Skip to main content

Table 2 Sensitivity analyses

From: Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials

 

All-cause mortality

  

Myocardial infarction

  

Stroke

  

RR (95%CI)

I2

N

RR (95%CI)

I2

N

RR (95%CI)

I2

N

Type of control

 Placebo

0.99 (0.95–1.04)

13

18

0.96 (0.88–1.05)

0

14

0.91 (0.85–0.98)

7

14

 Active

1.01 (0.95–1.08)

28

21

1.03 (0.96–1.11)

7

23

0.93 (0.79–1.08)

54

22

 Active only ACE inhibitors

1.04 (0.95–1.13)

46

8

1.01 (0.93–1.09)

0

9

0.98 (0.88–1.10)

0

8

Follow-up period

 ≤ 40 weeks

1.01 (0.91–1.14)

51

19

0.98 (0.88–1.10)

12

18

0.94 (0.74–1.20)

40

18

 > 40 weeks

1.00 (0.96–1.03)

0

20

1.03 (0.96–1.10)

0

19

0.90 (0.82–1.00)

45

18

Proportion of males

 ≤ 50%

0.93 (0.86–1.00)

0

6

1.02 (0.85–1.22)

37

5

0.76 (0.68–0.84)

0

5

 > 50%

1.02 (0.97–1.06)

23

33

1.01 (0.95–1.07)

0

32

0.96 (0.87–1.05)

28

31

Age

 ≤ 65 years

0.98 (0.88–1.09)

32

18

0.95 (0.85–1.06)

0

15

1.03 (0.80–1.34)

22

12

 > 65 years

1.01 (0.98–1.05)

10

20

1.04 (0.98–1.10)

0

21

0.92 (0.84–1.00)

41

23

BMI

 Normal range

0.84 (0.60–1.19)

31

7

0.81 (0.41–1.57)

0

6

1.21 (0.77–1.90)

0

5

 Overweight and obese

1.01 (0.98–1.04)

0

24

1.01 (0.96–1.07)

5

24

0.92 (0.83–1.01)

49

23

Elevated total cholesterol

 ≥ 200 mg/dL

0.98 (0.91–1.05)

15

10

0.99 (0.91–1.08)

0

8

0.82 (0.74–0.91)

6

7

Elevated LDL

 ≥ 120 mg/dL

1.01 (0.90–1.14)

36

7

0.97 (0.87–1.07)

0

6

0.86 (0.70–1.07)

45

5

Decreased HDL

 < 50 mg/dL

1.01 (0.95–1.08)

15

11

0.99 (0.89–1.09)

20

10

0.90 (0.82–0.98)

0

8

Elevated triglyceride

 ≥ 150 mg/dL

1.01 (0.94–1.08)

13

8

0.99 (0.90–1.09)

16

8

0.92 (0.83–1.01)

0

7

Proportion of smokers

 < 25%

0.91 (0.84–0.98)

2

12

0.99 (0.88–1.11)

0

13

0.81 (0.67–0.99)

41

12

 ≥ 25%

0.99 (0.95–1.05)

7

15

0.99 (0.91–1.01)

0

12

0.92 (0.87–0.98)

0

12

Hypertension

 Only patients with hypertension

0.98 (0.89–1.07)

0

12

1.02 (0.80–1.29)

27

12

0.82 (0.66–1.03)

57

13

Chronic heart failure (CHF)

 Only patients without CHF

0.97 (0.92–1.03)

0

11

0.99 (0.83–1.18)

43

12

0.85 (0.73–1.00)

47

11

 Only patients with CHF

1.00 (0.85–1.19)

75

6

1.06 (0.86–1.32)

0

8

1.04 (0.81–1.32)

14

8

Diabetes mellitus (DM)

 Only patients without DM

0.99 (0.38–2.61)

0

2

0.65 (0.26–1.59)

48

3

0.72 (0.50–1.04)

37

3

 Only patients with DM

1.04 (0.88–1.23)

0

7

0.99 (0.53–1.80)

67

4

1.31 (0.73–2.35)

30

3

Ischemic/coronary artery disease

 Only patients with ischemic/coronary artery disease

1.06 (0.91–1.22)

25

7

0.97 (0.88–1.07)

0

7

1.02 (0.84–1.24)

0

5

Chronic kidney disease

 Only patients with chronic kidney disease

0.86 (0.66–1.12)

50

8

0.99 (0.71–1.41)

20

9

1.08 (0.83–1.39)

0

8

  1. CI confidence interval; N number of studies; RR relative risk; ACE angiotensin-converting-enzyme
  2. Statistically significant results are emboldened